Global expansion HistoSonics is actively expanding offices in Asia (Taiwan and broader Eastern Asia) and pursuing collaborations with leading physicians and institutions across Taiwan and Asia, backed by TFDA approval—a prime signal for regional partnerships, distributor networks, and prospective clinical trial collaborations.

Clinical evidence The company aims to generate high-quality clinical evidence and advance additional indications through regional clinical research, offering opportunities to collaborate on multi-site studies, investigator-initiated trials, and data-driven sales narratives to hospitals and academic centers.

Training focus There is a clear emphasis on developing advanced physician training and education programs in the region, presenting a channel for medical education partnerships, trainer deployment, and certification programs that can drive adoption and speed to revenue.

Strategic visibility Recognition as one of the world’s most influential health and life science companies in 2026 amplifies credibility with healthcare networks, potential customers, and investors, enabling enhanced outreach, KOL engagement, and higher win rates in competitive bids.

Financing momentum A recent $250M financing round signals strong investor validation and runway for clinical deployment, commercialization, and capacity scaling, creating a favorable backdrop for joint ventures, co-development discussions, and enterprise-level procurement conversations.